Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.

Tytuł:
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
Autorzy:
Maxson JE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Ries RE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Wang YC; Children's Oncology Group, Monrovia, CA;
Gerbing RB; Children's Oncology Group, Monrovia, CA;
Kolb EA; Nemours Center for Cancer and Blood Disorders, Alfred I. duPont Hospital for Children, Wilmington, DE;
Thompson SL; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Guidry Auvil JM; Office of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Marra MA; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Ma Y; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Zong Z; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Mungall AJ; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Moore R; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Long W; Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada;
Gesuwan P; Office of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Davidsen TM; Office of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Hermida LC; Office of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Hughes SB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Farrar JE; Arkansas Children's Hospital Research Institute and Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR;
Radich JP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
Smith MA; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD;
Gerhard DS; Office of Cancer Genomics, National Cancer Institute, Bethesda, MD;
Gamis AS; Children's Oncology Group, Monrovia, CA; Division of Hematology/Oncology/Bone Marrow Transplantation, Children's Mercy Hospitals and Clinics, Kansas City, MO; and.
Alonzo TA; Children's Oncology Group, Monrovia, CA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA.
Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Children's Oncology Group, Monrovia, CA;
Źródło:
Blood [Blood] 2016 Jun 16; Vol. 127 (24), pp. 3094-8. Date of Electronic Publication: 2016 May 03.
Typ publikacji:
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2021- : [New York] : Elsevier
Original Publication: New York, Grune & Stratton [etc.]
MeSH Terms:
Mutation*
CCAAT-Enhancer-Binding Proteins/*genetics
Leukemia, Myeloid, Acute/*genetics
Receptors, Colony-Stimulating Factor/*genetics
Child ; Child, Preschool ; Cohort Studies ; Female ; Humans ; Infant ; Male
References:
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4683-7. (PMID: 8197119)
Br J Haematol. 2015 Aug;170(3):391-7. (PMID: 25858548)
Blood. 2011 Jul 28;118(4):1077-86. (PMID: 21636860)
Blood. 1994 Sep 15;84(6):1737-46. (PMID: 7521686)
Haematologica. 2013 May;98(5):e62-3. (PMID: 23508011)
Blood. 2013 Sep 5;122(10):1707-11. (PMID: 23896413)
J Biol Chem. 1998 Feb 6;273(6):3230-5. (PMID: 9452436)
Blood. 2002 Feb 15;99(4):1332-40. (PMID: 11830484)
Blood. 1999 Jan 15;93(2):447-58. (PMID: 9885206)
Leukemia. 2013 Sep;27(9):1870-3. (PMID: 23604229)
Nat Genet. 2001 Mar;27(3):263-70. (PMID: 11242107)
Semin Hematol. 2013 Oct;50(4):325-32. (PMID: 24246700)
Blood. 2004 Aug 1;104(3):667-74. (PMID: 15069015)
Blood. 1994 Sep 15;84(6):1760-4. (PMID: 7521688)
N Engl J Med. 2013 May 9;368(19):1781-90. (PMID: 23656643)
J Biol Chem. 2014 Feb 28;289(9):5820-7. (PMID: 24403076)
Blood. 2004 May 1;103(9):3305-12. (PMID: 14656892)
Leuk Res Rep. 2014 Aug 01;3(2):67-9. (PMID: 25180155)
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2985-8. (PMID: 7512720)
Blood. 2013 Nov 21;122(22):3628-31. (PMID: 24081659)
Blood. 2004 Apr 1;103(7):2744-52. (PMID: 14656889)
Blood. 2012 May 31;119(22):5071-7. (PMID: 22371884)
Leukemia. 2005 Mar;19(3):329-34. (PMID: 15674366)
Grant Information:
R00 CA190605 United States CA NCI NIH HHS; R01 CA114563 United States CA NCI NIH HHS; S10 OD020069 United States OD NIH HHS; U10 CA180899 United States CA NCI NIH HHS
Substance Nomenclature:
0 (CCAAT-Enhancer-Binding Proteins)
0 (CEBPA protein, human)
0 (CSF3R protein, human)
0 (Receptors, Colony-Stimulating Factor)
Entry Date(s):
Date Created: 20160505 Date Completed: 20180123 Latest Revision: 20210202
Update Code:
20240104
PubMed Central ID:
PMC4911865
DOI:
10.1182/blood-2016-04-709899
PMID:
27143256
Raport
Comment in: Blood. 2016 Jun 16;127(24):2946-7. (PMID: 27313323)
Erratum in: Blood. 2017 Jan 5;129(1):134. (PMID: 28057676)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies